Catalent Inc (CTLT) Scheduled to Post Earnings on Monday
Catalent Inc (NASDAQ:CTLT) is scheduled to release its earnings data after the market closes on Monday, November 6th. Analysts expect Catalent to post earnings of $0.20 per share for the quarter.
Catalent (NASDAQ:CTLT) last posted its quarterly earnings data on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The business had revenue of $616.90 million for the quarter, compared to analysts’ expectations of $547.48 million. During the same quarter last year, the firm earned $0.52 earnings per share. The business’s revenue was up 15.9% on a year-over-year basis.
Catalent Inc (NASDAQ CTLT) opened at $42.70 on Friday.
ILLEGAL ACTIVITY WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/catalent-inc-ctlt-scheduled-to-post-earnings-on-monday/1677101.html.
CTLT has been the topic of a number of research analyst reports. Bank of America Corporation reiterated a “buy” rating and issued a $38.00 target price (up previously from $37.00) on shares of Catalent in a report on Friday, July 21st. BidaskClub cut Catalent from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Piper Jaffray Companies reiterated a “buy” rating and issued a $45.00 target price on shares of Catalent in a report on Tuesday, August 29th. Finally, J P Morgan Chase & Co reiterated a “buy” rating and issued a $40.00 target price on shares of Catalent in a report on Tuesday, August 29th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $41.67.
In other Catalent news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.